�The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a clinical trial with the unwritten immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID� (lenalidomide) and VELCADE� (bortezomib) for Injection.
Paul Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute, is leading the Phase 1 / 2, multicenter, randomized, open-label, dose-escalation study. The Phase 1 study is designed to determine maximum tolerated dose of single-agent pomalidomide piece the Phase 2 randomised study will compare the oral compound's efficacy alone against its combination with dexamethasone.
"This potent new immunomodulator, which is in the same class as thalidomide and lenalidomide, volition hopefully be successful in treating patients who have relapsed or who don't respond to currently usable treatment options. We are excited to be testing pomalidomide in this setting and are optimistic that it will meaningfully add to our therapeutic options for our patients," said Dr. Richardson.
"This fresh clinical tribulation brings the total figure of studies that the MMRC has initiated to fourteen. We are thrilled to advance this study in our mission to identify and prioritize the most bright treatments for patients with multiple myeloma", said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, and a myeloma patient.
Pomalidomide is an IMiDs compound, a member of Celgene's proprietary mathematical group of novel oral immunomodulatory agents that impede or stabilize disease through respective mechanisms of action, including anti-angiogenic natural process.
Celgene's lead IMiDs compound, REVLIMID� (lenalidomide) continues to demonstrate unprecedented overall endurance in multiple myeloma as well as significant clinical potential across a broad range of blood cancers. To particular date, REVLIMID has obtained orphan drug identification for myelodysplastic syndrome in the European Union (EU), United States (US), and Australia, orphan drug assignment for multiple myeloma (MM) in the EU, US, Australia and Switzerland, and orphan do drugs designation for chronic lymphocytic leukemia (CLL) in the EU and US. REVLIMID is presently approved for use in the US and Canada for the treatment of patients with transfusion-dependent genus Anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetical abnormality with or without additional cytogenetic abnormalities. REVLIMID is likewise approved for use in the EU, US and Switzerland for the treatment of multiple myeloma in combination with dexamethasone in patients world Health Organization have standard at least one prior therapy, and Australia for patients with multiple myeloma whose disease has progressed after nonpareil therapy.
About IMiDs�
IMiDs compounds ar proprietary novel small molecule, orally uncommitted compounds that modulate the immune system and other biologically significant targets through multiple mechanisms of action, including angiogenesis inhibition, inflection of the levels of key pro-inflammatory and regulative cytokines and immune jail cell co-stimulation (eg, T cells, NK cells)
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company occupied primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through factor and protein regulation. For more information, please chatter the Company's website at http://www.celgene.com.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Foundation (MMRC), a 509a3 organization, was founded in 2004 by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation, to speed the development of novel and combination treatments for patients with multiple myeloma by facilitating innovative clinical trials and correlative studies.
At the core of the MMRC model is an surpassing Executive Committee, based in Norwalk, Conn., which provides strategic inadvertence of the MMRC's drug development projects. The MMRC's 15 Member Institutions ar among the prominent academic research centers worldwide: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Indiana University, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, University of California - San Francisco, and Washington University.
The MMRC model besides includes an advanced Tissue and Data Bank, which serve as a "bridge" between laboratory and clinical research conducted by the MMRC and a critical resource in advancing MMRC clinical trials and correlative science studies.
As a results-driven organization, the MMRC has facilitated to escort 15 Phase I and II clinical trials of the most promising novel compounds and combination approaches. MMRC clinical trials ar designed to include correlative studies to better infer what drugs are to the highest degree effective in treating several sub-groups of myeloma patients, laying the foundation for the eventual development of personalized medicines as a treatment for myeloma.
The Multiple Myeloma Research Consortium
View drug information on Revlimid; Velcade.
More information
